PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
- PsiOxus Therapeutics Ltd has updated the agreement to advance its clinical collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate PsiOxus' tumor re-engineering platform, in combination with BMY's Opdivo (nivolumab) to treat a range of tumor types.
- The first stage of this collaboration combined BMY's Opdivo with PsiOxus' enadenotucirev in Phase 1 SPICE study to evaluate the combination's safety and tolerability and optimize the combination intravenous dosing regimen.
- The revised collaboration will build upon the initial study data and will combine Opdivo with PsiOxus' NG-641.
- NG-641 is a tumor re-engineering product using PsiOxus' Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform based upon the enadenotucirev vector.
- Under the terms of this agreement, PsiOxus will be responsible for conducting the Phase 1 study.
- Patient recruitment is expected to start in the third quarter of this year.
- Price Action: BMY shares are up 0.2% at $62.1 in the premarket trading on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs cancer OpdivoBiotech News Health Care Contracts General
